Triple antiviral drug shows early promise in COVID-19 trial


LONDON: A triple drug combination of antiviral medicines helped relieve symptoms in patients with mild to moderate COVID-19 infection and swiftly reduced the amount of virus in their bodies, according to results of a small trial in Hong Kong. The trial, which involved 127 patients, compared those given the combination drug ? made up of the HIV medicine lopinavir–ritonavir, the hepatitis drug ribavirin, and the multiple sclerosis treatment interferon beta ? with a control group given just the HIV drug.